Cannon Global Investment Management’s Century Therapeutics IPSC Stock Holding History

Cannon Global Investment Management’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$111K	Buy	+49,000	New	+$103K	0.22%	78

Other funds holding IPSC

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Point72 Asset Management

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Cannon Global Investment Management's IPSC Position: Q1 2026 in Review

Cannon Global Investment Management opened a new position in Century Therapeutics (IPSC) in Q1 2026: 49,000 shares worth $111K. The stake represents 0.22% of the portfolio and ranks #78 among its holdings.

72 funds tracked by Wall St. Rank hold IPSC as of Q1 2026.

Cannon Global Investment Management held 49,000 shares of Century Therapeutics worth $111K as of Q1 2026.
Century Therapeutics was a new Cannon Global Investment Management position in Q1 2026.
Century Therapeutics made up 0.22% of Cannon Global Investment Management's portfolio in Q1 2026, its #78 holding.
72 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2026.

Based on Cannon Global Investment Management's 13F filing for Q1 2026, filed 21 Apr 2026.